Kornimate/medical-research-clean huggingface dataset:
impact of supplementation with low molecular weight hydrolyzed collagen and verisol on the expression of lines, skin quality, and levels of klotho, vegf, and tgf-beta in the eye region

Conditions: Skin Health; Collagen Supplementation; Growth Factors

Summary: skin is the largest organ of the human body and performs various vital functions, including protection against external agents, regulation of body temperature, and sensory perception. as we age, our skin undergoes a series of changes that can be noticeable both visually and physically. one of the most evident changes is the appearance of wrinkles and fine lines, resulting from decreased skin elasticity and reduced production of collagen and elastin. nutrition plays a key role in skin health, influencing its structure, function, and ability to defend against damage and diseases. however, it is unknown to what extent supplementation with different types of collagens can attenuate these effects in middle-aged women. therefore, the present study aims to recruit 150 middle-aged women (35-58 years old) who will be randomized into three groups, verisol collagen 2.5 g/day, peptech collagen 2.5 g/day, and peptech collagen 10 g/day, 7 days a week, for 3 months. skin hydration, oiliness, and flexibility, as well as the number and depth of expression lines, will be evaluated, along with plasma levels of klotho, vegf, and tgf-beta. data will be analyzed, and graphs constructed using graphpad prism 5.0 software (california, usa). the normality distribution of the data will be assessed by the kolmogorov-smirnov test. data with parametric distribution will be subjected to paired student's t-test for intragroup comparison, and unpaired t-test will be used for comparison between groups. significance levels will be considered statistically different for p\<0.05.


Eligibility criteria:
inclusion criteria: * "inclusion criteria require that volunteers be between 35 and 58 years old, have been sedentary for at least one year, and, after reading and understanding all stages of the study, agree to and sign the informed consent form (icf). exclusion criteria: * "exclusion criteria include undergoing facial aesthetic procedures involving hyaluronic acid or botulinum toxin, being an active or passive smoker within the past 3 years, using protein- or amino acid-based supplements within the past 6 months, or using cosmetics with skin-repairing properties in the orbicularis oculi region.

Keywords: skin health collagen supplementation growth factors
elevate (evaluation of left ventricular autothreshold) 3.0

Conditions: Heart Failure

Summary: this 3rd phase of the elevate study. the study is collecting data from an implanted crt-d device to evaluate a new feature for future heart failure devices.

elevate 3.0 is an acute, prospective, multicenter feasibility study which is randomized within a patient test sequence and pulse width. the study is designed to characterize the performance of lvat (left ventricular authothreshold) feature.

Eligibility criteria:
inclusion criteria: * patients who are age 18 or above, or of legal age to give informed consent specific to state and national law * patients who have a cognis crt-d device implanted for at least 24 hours, with or without an active right atrial lead * patients who have an active lv bipolar or unipolar lead * patients who have an active rv defibrillation lead * patients who are willing and capable of participating in all testing associated with this clinical investigation exclusion criteria: * patients who have a cognis crt-d that has less than or equal to one year of battery life remaining * patients who are pacemaker-dependent as defined as vvi 40 without intrinsic atrial or ventricular activity * patients who will not tolerate a pacing pause of up to 6 seconds * patients with a pre-existing unipolar pacemaker * patients who are unable or unwilling to maintain a supine or sitting position for 20-50 minutes * patients enrolled in any concurrent study, without boston scientific crm written approval * women who are pregnant;women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.

Keywords: heart failure autothreshold pacing crt-d recipients left ventricular evoked response signals
renal magnetic resonance (mr) elastography in healthy volunteers

Conditions: Healthy

Summary: mr elastography is a new technique aimed at non-invasively measuring the stiffness of tissues. it has recently given interesting results in the assessment of liver fibrosis. the objectives of the current study are: 1. to develop an imaging protocol for mr elastography of the kidneys; 2. to calculate the stiffness of normal kidneys; 3. to evaluate the variability of the measurements of kidney stiffness by repeating the procedure twice on the same volunteers.


Eligibility criteria:
inclusion criteria: * age between 18 and 40 * signed informed consent form * insured by the french social security exclusion criteria: * pregnancy * personal or familial history of kidney disease * hypertension * diabetes * contraindication to mri

Keywords: mr elastography kidney fibrosis
early use of noninvasive positive pressure ventilation for intro-pulmonary acute lung injury

Conditions: Acute Lung Injury

Summary: to assess the safety and efficacy of noninvasive positive pressure ventilation for patients with intro-pulmonary pulmonary acute lung injury and compare this with high-concentration oxygen therapy.


Eligibility criteria:
inclusion criteria: 1. acute onset; 2. a clinical presentation of respiratory distress; 3. arterial oxygen tension/inspired oxygen fraction (pao2/fio2) \ 200 mmhg while breathing oxygen delivered by a conventional venturi device at a maximum concentration (50%); 4. presence of bilateral pulmonary infiltrates on posteroanterior chest radiograph; 5. no evidence of left heart failure as assessed by echocardiography and/or a pulmonary artery wedge pressure of \<18 mm hg. 6. the cause of ali is consider to be intro-pulmonary. exclusion criteria: 1. age \<18 yrs; 2. glasgow coma scale \< 11; 3. airway or facial injury; 4. pneumothorax or pneumomediastinum; 5. unable to spontaneously clear secretions from the airways; 6. cardiogenic shock or severe hemodynamic instability (systolic blood pressure \<90 mmhg associated with decreased urinary output (\<20 ml.h-1) despite fluid repletion and use of vasoactive agents) of other causes; 7. severe ventricular arrhythmia or unstable myocardial ischemia; 8. severe organ dysfunction (sequential organ failure assessment score \> 3); 9. end-stage patients who were expected to survive \< 6 months; 10. severe abdominal distension; 11. refusal to receive nppv; 12. the cause of ali is consider to be extrapulmonary; 13. unable to cooperate with nppv application; 14. active upper gastrointestinal bleeding.

Keywords: ali;noninvasive positive pressure ventilation
class ii correction study using the invisalign system

Conditions: Malocclusion

Summary: to demonstrate that growing teenagers which present up to full cusp class ii malocclusions can be treated using the invisalign system.

the invisalign® system consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. each aligner is worn for about two weeks, then replaced by the next in the series until the final position is achieved. for years, orthodontists and dentists have used removable appliances for orthodontic treatment. today, with the application of computer technology and custom manufacturing, invisalign treats a broader range of cases with greater precision.

Eligibility criteria:
inclusion criteria: * subject must have fully erupted dentition excluding 2nd and 3rd molars * age range 11-19 years old * subject that requires bilateral class ii correction and must require at least 3mm of correction as measured by first molar relationship exclusion criteria: * subject who has unerupted, erupting, partially erupted dentition (except for 2nd and 3rd molars) * subject who has spaces between adjacent teeth larger than 3mm * subject with active caries * subject with periodontal disease * subject does not have at least 1st molar fully captured in pvs (polyvinyl siloxane material ) impression or intraoral scan. * subject with tmd (temporomandibular joint dysfunction) symptoms * subject has undergone pre-treatment with any orthodontic appliance (any previous treatment prior to study) * subject has known allergy to latex and plastic * subjects who are pregnant or will become pregnant during treatment

Keywords: orthodontic orthodontic treatment clear aligners malocclusion
a study of the safety, tolerability and pharmacokientics of ro5545965 in patients with schizophrenia on risperidone

Conditions: Schizophrenia

Summary: this randomized, double-blinded, placebo-controlled study will investigate the safety, tolerability, and pharmacokinetics of multiple doses of ro5545965 administered orally to psychiatrically stable patients with schizophrenia receiving risperidone.


Eligibility criteria:
inclusion criteria: * males or females aged \>/= 18 years and \</= 60 years * clinically stable, mild or moderate schizophrenia * on stable antipsychotic treatment for the last 6 months * generally healthy in the investigator's opinion, based on assessment of medical history, physical examination, vital signs, electrocardiogram (ecg), and the results of the hematology, clinical chemistry, urinalysis, serology, and other laboratory tests * willingness to be hospitalized for approximately 3 weeks * bmi \> 18.5 kg/m2 and \< 38 kg/m2 * use of highly effective contraception as defined by the study protocol. men must also not donate sperm until at least 30 days after the last dose, and women cannot be pregnant or breastfeeding exclusion criteria: * treatment with antiparkinson medication including anticholinergic drugs * treatment with depot antipsychotic medication within the last three months prior to screening * participation in a clinical trial with an investigational drug or device \< 3 months prior to screening * smokes more than 20 cigarettes per day * current drug abuse (excluding nicotine) or drug abuse within 3 months prior to the screening visit * any donation of blood or significant blood loss within three months prior to first administration of the study drug * use of prohibited medications (including vitamins or herbal remedies) taken within 14 days or within 5 times the elimination half-life of the medication (whichever is longer) before the first study drug administration
effects of a 12-week strength training program in women with myotonic dystrophy type 1

Conditions: Myotonic Dystrophy 1

Summary: 20 women with myotonic dystrophy type 1 (dm1) will complete a 12-week lower-limb strength training program. the training program consist of 3 series of 6 to 8 maximal repetitions of 5 different exercises: leg extension, leg press, hip abduction, squat and plantar flexion. training sessions will be closely supervise and take place twice a week. it is hypothesize that the training program will induce muscular hypertrophy despite the genetic defect. the training program should also have positive effects on function. the participants will be evaluated at baseline, week 6, week 12, month 6 and month 9 to quantify the effects of the training program and if these effects will be maintained over time.


Eligibility criteria:
inclusion criteria: * dm1 diagnosis must be confirmed by genetic analysis; * women sex, aged between 30 and 65 years old; * be able to walk without assistance; * consent of the neurologist must be given to participate in this study; * must reside in the saguenay-lac-st-jean region; * subjects must be able to give their consent freely and voluntarily. exclusion criteria: * patients with any other form of muscular dystrophy are excluded; * any contraindication for strenuous exercise or muscle biopsy.
the role of migraine prophylaxis agent topiramate in treating patients with sudden sensorineural hearing loss

Conditions: Sudden Deafness; Sudden Sensorineural Hearing Loss

Summary: migraine and sudden sensorineural hearing loss(ssnhl) are two related disorders. a systemic steroid is usually used to treat ssnhl but the role of migraine prophylaxis medication remained unknown. mehdi abouzari et al. found a better improvement when combining topiramate and nortriptyline with steroids in a retrospective study. however, a prospective study with randomization is needed to elucidate the efficacy of these agents. this is a clinical study using medication approved and currently prescribed in the clinic. the included patients were those who came to the clinic and were diagnosed with ssnhl within 14 days of onset. those patients were asked whether they agreed to participate in this clinical trial. patients who were diagnosed with ssnhl but were later found to be other diseases such as meniere's disease and cerebellopontine angle will be excluded from this study. the involved patients were randomized divided into two groups. both groups received systemic steroids with/without intratympanic steroids. the experimental group receives additional oral topiramate for 6 weeks. follow-up time is at least 3 months. this study is multi-center. location of the study is performed at chang gung memorial hospital linkou branch, taipei branch, taoyuan branch, and new taipei municipal tucheng hospital.

once the patients were diagnosed with ssnhl, detailed information of the clinical trial will be introduced. if the patient agreed to participate, he/she will be randomized. the experimental group receives additional oral topiramate for 6 weeks. both groups follow up at the clinic for at least 3 months. the pure tone audiometry and speech audiometry will be measured at the initial and end of follow-up. patients who were later diagnosed with cerebellopontine angle tumors, stroke, or meniere's disease, will be excluded from this study. the audiometry and other hearing outcomes will be analyzed at the end of the study. the treatment efficacy, and prognostic factors will be analyzed and reported. data regarding adverse effects and drop-out will also be collected and reported.

Eligibility criteria:
inclusion criteria: * age \> 20 * confirmed diagnosis of unilateral sudden sensorineural hearing loss(ssnhl) * treatment started 14 days within onset of ssnhl exclusion criteria: * previous ssnhl history * previous middle ear disorder such as chronic otitis media, or previous ear surgery * meniere's disease and fluctuating hearing loss patients * pregnancy or trying to become pregnant * leukemia, hemodialysis, and patients who received chemotherapy before. * previous head and neck radiotherapy * cerebellopontine angle tumors such as vestibular schwannoma * patients with moderate to severe hepatic insufficiency * patients with major depression disorder or suicide attempt * patients with glaucoma

Keywords: sudden deafness ssnhl migraine topiramate sudden sensorineural hearing loss
exercise training effects in patients with heart failure

Conditions: Chronic Heart Failure

Summary: chronic heart failure (chf) is a common syndrome characterized by several central hemodynamic and peripheral vascular and muscle abnormalities including autonomic imbalance, neuro-hormonal over-activation and decreased oxidative status. in patients suffering from chf, exercise confers several beneficial effects on the cardiovascular and peripheral systems, mainly by continuous aerobic training. however, interval aerobic training has also been validated as an alternate form of training that increases the exercise capacity of patients who are in chf. recent studies have suggested that resistance training alone or as a complementary program besides the traditionally aerobic continuous training might exert favorable effects. however, little it is known about the combined effects of interval and strength training in chf patients. aim of this prospective randomized controlled study was to investigate the effects of combined interval and strength training comparing to interval training alone in chf patients.


Eligibility criteria:
inclusion criteria: * stable systolic heart failure * nyha functional class ≤ iii * optimal medical treatment exclusion criteria: * contraindications for a maximal cardiopulmonary exercise testing (cpet) according to the american thoracic society/american college of chest physicians statement * moderate to severe copd

Keywords: interval training strength training exercise capacity chronic heart failure cardiac rehabilitation
study evaluating single doses of ppm-204 on the electrical pathways of the heart

Conditions: Diabetes Mellitus

Summary: a study evaluating the safety of a high and low dose of ppm-204 on the electrical pathways of the heart.


Eligibility criteria:
inclusion criteria: * men or women, aged 18 to 55 years * body mass index in the range of 18 to 30 kg/m2 * healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ecg exclusion criteria: * history of cardiac, thyroid, muscle, or kidney abnormalities * a family history of long qt syndrome and/or sudden cardiac death * history of any clinically significant drug allergy, hypersensitivity to sulfonomides or the quinolone class of antibiotics
investigating the effect of a smartphone-based serious game on depressive symptoms.

Conditions: Depressive Symptoms

Summary: the objective of the present project is to study the effect of a smartphone-based serious game intervention for depressive symptoms. the serious game is based on cognitive behavior therapy cbt, being behavioural activation and the promotion of physical activity one of the most important components.

due to the current covid-19 pandemic and the effects of quarantine on people's daily lives, a dramatic increase in people suffering from symptoms of depression is expected; one of the most common mental disorders globally, the primary cause of suicide deaths in europe and the major contributor to the overall global burden of disease. although there are effective treatments for depression, more than half of those affected worldwide (and more than 90% in many countries) do not receive these treatments. the dominant model of treatment delivery (individual face-to-face therapy) will not be enough to reach the majority of people who need treatment. hence, one of the most important challenges within this scope is the design of new forms of treatment delivery to maximize the efficacy and dissemination of psychological treatment. the use of the information and communication technologies (icts) has allowed a new effective ways of treatment, endorsed by several studies; and the use of serious video games as a partial or complete form of treatment, whose own characteristics make them potentially effective for the treatment of mental health, has opened the possibility of a still very new field of study. the arrival of smartphones has increased the possibilities of designing online therapies for mental health and facilitated the use of games as therapy. therefore, the objective of the present project is to study the effect of a smartphone-based serious game intervention for depressive symptoms through a two armed pilot randomized control trial. a minimum of 40 participants diagnosed with mild to moderate depression symptoms will be randomly assigned to one of the two experimental conditions: a smartphone-based serious game condition, and a waiting list control condition. the researchers' hypothesis is that the smartphone-based serious game intervention will produce a significant improvement in depressive, anxious symptomatology and improved well-being after treatment compared to the waiting list control group.

Eligibility criteria:
inclusion criteria: * 18-65 years old * being able to read and understand spanish * being able to use a smartphone * having an android smartphone with internet connection * suffering from mild to moderate depressive symptoms (from 14 to 28 on the beck depression inventory-ii \[bdi-ii\] exclusion criteria: * suffering a severe mental disorder: bipolar disorder, alcohol and/ or substance dependence disorder, psychotic disorder, or dementia * having a high suicide risk (ideation or plan assessed by the mini and item 9 of the bdi-ii) * receiving another psychological treatment while the study is still ongoing.
effect of audiovisual education on breast cancer

Conditions: Breast Cancer

Summary: this study was conducted as a double-blind randomised controlled trial to determine the effect of education using audio-visual methods and simulation techniques on breast cancer screening and breast cancer fears in illiterate women. the study was conducted in the villages of a district in the south of turkey with a distance of over 100 km to health institutions. the sample size of the study was calculated with the g\*power 3.1 programme based on the mean breast cancer fear scores (22.42±8.30 for those without family history and 28.14±6.23 for those with family history) in a study, with a 95% confidence interval, 5% margin of error, 0.92 effect size and 95% power. as a result of this analysis, the minimum sample size required was determined as 64 people in total. however, a total of 120 women were included in the study in order to increase the power of the research, to prevent possible data loss and to make the results more reliable. participants were divided into intervention (n=60) and control (n=60) groups by simple random sampling method.


Eligibility criteria:
inclusion criteria: 1. being between the ages of 40-69 (republic of turkey ministry of health, 2020a). 2. being a woman living in rural areas. 3. being an illiterate woman. 4. not being diagnosed with breast cancer. 5. not being pregnant, breastfeeding or puerperant. 6. accepting to participate in the study. 7. absence of a mental illness. 8. no communication barriers exclusion criteria: 1. not having completed the given training sessions 2. having had problems with breast cancer before. 3. having breast conserving surgery for any reason.